Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters

被引:57
|
作者
Schlessinger, Avner [1 ,2 ]
Khuri, Natalia [1 ,2 ,4 ]
Giacomini, Kathleen M. [1 ,2 ,5 ]
Sali, Andrej [1 ,2 ,3 ]
机构
[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Calif Inst Quantitat Biosci, San Francisco, CA 94158 USA
[3] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA
[4] Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94158 USA
[5] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94158 USA
基金
美国国家卫生研究院;
关键词
Membrane transporter; comparative modeling; ligand docking; protein function prediction; structure-based ligand discovery; ORGANIC CATION TRANSPORTER; MEMBRANE-PROTEIN STRUCTURE; STRUCTURE-BASED DISCOVERY; AMINO-ACID TRANSPORTER-1; TRANSMEMBRANE DOMAIN-I; BLOOD-BRAIN-BARRIER; BACTERIAL HOMOLOG; GENETIC-VARIATION; CRYSTAL-STRUCTURE; FUNCTIONAL-CHARACTERIZATION;
D O I
10.2174/1568026611313070007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Solute Carrier (SLC) transporters are membrane proteins that transport solutes, such as ions, metabolites, peptides, and drugs, across biological membranes, using diverse energy coupling mechanisms. In human, there are 386 SLC transporters, many of which contribute to the absorption, distribution, metabolism, and excretion of drugs and/or can be targeted directly by therapeutics. Recent atomic structures of SLC transporters determined by X-ray crystallography and NMR spectroscopy have significantly expanded the applicability of structure-based prediction of SLC transporter ligands, by enabling both comparative modeling of additional SLC transporters and virtual screening of small molecules libraries against experimental structures as well as comparative models. In this review, we begin by describing computational tools, including sequence analysis, comparative modeling, and virtual screening, that are used to predict the structures and functions of membrane proteins such as SLC transporters. We then illustrate the applications of these tools to predicting ligand specificities of select SLC transporters, followed by experimental validation using uptake kinetic measurements and other assays. We conclude by discussing future directions in the discovery of the SLC transporter ligands.
引用
收藏
页码:843 / 856
页数:14
相关论文
共 50 条
  • [41] Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration-resistant prostate cancer
    Kushwaha, Prem P.
    Verma, Shiv S.
    Shankar, Eswar
    Lin, Spencer
    Gupta, Sanjay
    MOLECULAR CARCINOGENESIS, 2022, 61 (04) : 397 - 407
  • [42] The Human SLC25A33 and SLC25A36 Genes of Solute Carrier Family 25 Encode Two Mitochondrial Pyrimidine Nucleotide Transporters
    Di Noia, Maria Antonietta
    Todisco, Simona
    Cirigliano, Angela
    Rinaldi, Teresa
    Agrimi, Gennaro
    Iacobazzi, Vito
    Palmieri, Ferdinando
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (48) : 33137 - 33148
  • [43] Involvement of solute carrier transporters SLC25A17 and SLC27A6 in metabolic reprograming of castration-resistant prostate cancer.
    Kushwaha, Prem P.
    Verma, Shiv S.
    Shankar, Eswar
    Lin, Spencer
    Gupta, Sanjay
    CANCER RESEARCH, 2022, 82 (12)
  • [44] FUNCTIONAL CHARACTERIZATION OF MAJOR SOLUTE CARRIER (SLC) TRANSPORTERS INVOLVED IN DRUG-DRUG INTERACTIONS USING A POLARIZED MDCK MODEL
    Huang, Yong
    Warren, Mark
    Jahic, Mirza
    Kosaka, Alan
    Zhang, John
    Huang, Jane
    DRUG METABOLISM REVIEWS, 2012, 44 : 142 - 143
  • [45] The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships
    J. Geyer
    T. Wilke
    E. Petzinger
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 372 : 413 - 431
  • [46] SOLUTE CARRIER FAMILY (SLC22) TRANSPORTERS MEDIATED SUBSTRATE CHARACTERIZATION OF 22 ANTI-TB DRUGS.
    Parvez, M.
    Kaisar, N.
    Lee, Y.
    Shin, H.
    Jung, J.
    Shin, J. -G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S41 - S41
  • [47] A Substrate Access Tunnel in the Cytosolic Domain Is Not an Essential Feature of the Solute Carrier 4 (SLC4) Family of Bicarbonate Transporters
    Shnitsar, Volodymyr
    Li, Jing
    Li, Xuyao
    Calmettes, Charles
    Basu, Arghya
    Casey, Joseph R.
    Moraes, Trevor F.
    Reithmeier, Reinhart A. F.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (47) : 33848 - 33860
  • [48] The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships
    Geyer, J
    Wilke, T
    Petzinger, E
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 372 (06) : 413 - 431
  • [49] Structure modeling of γ-aminobutyric acid transporters - Molecular basics of ligand selectivity
    Latka, Kamil
    Jonczyk, Jakub
    Bajda, Marek
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 158 : 1380 - 1389
  • [50] The genetic landscape of the human solute carrier (SLC) transporter superfamily
    Lena Schaller
    Volker M. Lauschke
    Human Genetics, 2019, 138 : 1359 - 1377